[144] BridgeBio Pharma, Inc. SEC Filing

Rhea-AI Filing Summary

International Flavors & Fragrances Inc. (NYSE: IFF) filed an 8-K on Aug 5 2025. Item 2.02 furnishes a press release (Exhibit 99.1) with Q2 2025 results and announces a live webcast on Aug 6 2025 at 9:00 a.m. ET; a recorded replay will remain on the investor‐relations site for one year.

Item 8.01 discloses a new $500 million share-repurchase program. The authorization has no expiration date. Repurchases can occur via open-market, privately negotiated or Rule 10b5-1 trades and will be funded by cash on hand and operating cash flow. The board will periodically review and may modify the program’s size or duration.

• Exhibit 99.1: Q2 2025 earnings press release (furnished, not filed).
• Exhibit 104: cover-page Inline XBRL.
• Listed securities: common stock (IFF) and 1.800% senior notes due 2026.

No other material events or financial statements were included in this report.

Insights

Equity Research Analyst

TL;DR: $500 m buyback adds shareholder-friendly catalyst; earnings detail not in filing.

The newly authorized $500 million repurchase (~5-6 % of market cap) signals management’s confidence in cash generation and valuation. Lack of term flexibility lets IFF pace purchases with liquidity and leverage targets, supporting EPS accretion. Because Item 2.02 only furnishes a press release, investors must review Exhibit 99.1 for core metrics and margin trajectory before revising models. Overall, the filing is modestly positive, offering capital-return upside without introducing new risks.

Corporate Governance Specialist

TL;DR: Board’s open-ended authorization increases capital-allocation flexibility.

The board empowered management to execute repurchases through multiple channels, including 10b5-1 plans, limiting blackout constraints and potential insider-trading concerns. Open-ended duration avoids recurring approvals and may improve execution timing, but periodic board reviews retain oversight. No material adverse events are disclosed, and governance practices align with peer norms.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	17167	841183.00	189880720	08/05/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/05/2025	Stock Option Exercise	Issuer			17167	08/05/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)